Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500.

Orthopaedic clinicians should be cautious about recommending TB-500 due to the lack of validated human efficacy and safety data.

Summary and findings

This narrative review evaluated the molecular rationale, safety, and efficacy of TB-500 in the context of orthopaedic practice. The review highlights the limited clinical validation of TB-500 and its distinction from full-length thymosin beta-4. No FDA-approved indications or controlled human efficacy evidence for TB-500 in musculoskeletal applications were reported.

Abstract

Peptide-based products, particularly Body Protection Compound-157 (BPC-157), and thymosin beta-4 (TB-4), and products marketed as TB-500, are increasingly promoted for musculoskeletal recovery despite limited clinical validation. This narrative review evaluated their molecular rationale, direct musculoskeletal evidence, human safety and efficacy data, product quality concerns, regulatory status, antidoping implications, and relevance to orthopaedic counseling. PubMed/MEDLINE, EMBASE, and Scopus were searched from inception through June 2026, with additional review of primary regulatory and antidoping sources. BPC-157 has the largest bod of direct musculoskeletal preclinical evidence, including predominantly small-animal studies involving tendon, ligament, muscle, inflammatory joint disease, and bone. However, human musculoskeletal evidence is limited to one small retrospective uncontrolled case series without validated outcome measures. Validated dosing, pharmacokinetic, and long-term safety data are lacking. TB-4 has broader experimental and human experience in ophthalmic, dermatologic, and cardiovascular applications, but direct musculoskeletal evidence remains limited to in vitro and rodent studies. These nonorthopaedic findings cannot establish musculoskeletal efficacy or safety. TB-500 is a distinct seven amino-acid fragment of TB-4 that is frequently conflated with full-length TB-4 despite the absence of validated biologic or clinical equivalence. Commercial products marketed also raise concerns regarding identity, purity, concentration, sterility, and manufacturing consistency. None of these agents has an FDA-approved musculoskeletal indication, validated orthopaedic treatment protocol, or controlled human orthopaedic efficacy evidence. Orthopaedic clinicians should specifically ask about peptide use, distinguish preclinical plausibility from clinical validation, address product quality and safety uncertainties, and counsel athletes regarding antidoping restrictions. Routine clinical use cannot be currently recommended.

Limitations

Not reported in abstract.

Elsewhere in the TB-500 (Thymosin Beta-4 Fragment) corpus